Physician profile
Cassandra Johnson
NPI 1689168817
$4,395.70
in general payments reported to CMS, 2019-2025
21 companies · $1,496 in 2025
The $1,496 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $327 · 2023: $1,070 · 2024: $1,503 · 2025: $1,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,802 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.93 |
| Education | $266.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.64 | 2022-2025 | |
| Janssen Biotech, INC. | $561.49 | 2022-2025 | Tremfya |
| Pfizer INC. | $365.57 | 2022-2025 | |
| Ucb, INC. | $360.15 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $353.27 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $306.02 | 2023-2025 | |
| Genzyme Corporation | $255.42 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $253.15 | 2022-2025 | Blu-U, Odomzo, Winlevi |
| Amgen INC. | $236.51 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $202.38 | 2022-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $140.26 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $134.13 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $103.70 | 2024 | Sotyktu |
| Organon LLC | $73.40 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $61.75 | 2023-2024 | Idacio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.91 | 2024 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $52.60 | 2025 | Nemluvio |
| Merz North America, INC. | $23.84 | 2023 | Xeomin |
| Botanix Sb INC | $23.79 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $16.25 | 2023 | Bexsero |
| Biofrontera INC. | $14.47 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.